BioNTech’s rapid growth in the past financial year has significantly increased the workload of its committees. As this is also to be expected for the financial year 2022, the shareholders passed the Management Board and Supervisory Board’s proposal to remunerate committee work separately. An ordinary committee member will receive an additional annual remuneration of €5,000 per committee in the future and committee chairs will be remunerated with €15,000 per year, with the exception of the Audit Committee chair who receives €30,000 per year.
BNTX $$$$$$
BNTX $$$$$$
GLTA !
Recent BNTX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 12:03:17 PM
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 05/22/2026 09:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 08:18:28 PM
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 • GlobeNewswire Inc. • 05/15/2026 08:15:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:04:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:09:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:07:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:05:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:03:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:02:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/12/2026 10:56:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 12:20:03 PM
- BioNTech Announces New ADS Repurchase Program • GlobeNewswire Inc. • 05/07/2026 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/05/2026 10:49:47 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/05/2026 10:47:32 AM
- BioNTech Announces First Quarter 2026 Financial Results and Corporate Update • GlobeNewswire Inc. • 05/05/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:02:44 PM
- BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 • GlobeNewswire Inc. • 04/21/2026 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/13/2026 11:55:50 AM
- BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer • GlobeNewswire Inc. • 04/11/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 08:15:44 PM
- Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:16:07 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 10:04:48 PM
